Epidemiology and Drug Resistance of Pulmonary Nocardiosis Among Tuberculosis-Suspected Patients in Guangzhou, China

中国广州疑似结核病患者肺诺卡氏菌病的流行病学及耐药性研究

阅读:1

Abstract

OBJECTIVE: This study aimed to analyze the detection characteristics, species distribution, and drug susceptibility profiles of Nocardia isolates among tuberculosis-suspected patients in the Guangzhou region, thereby offering valuable insights for clinical diagnosis and treatment. METHODS: This study included 77,550 clinical samples collected from tuberculosis-suspected patients. All specimens were cultured using the MGIT 960 liquid culture system. Culture-positive isolates underwent acid-fast staining, followed by Nocardia subculture purification and species identification using mass spectrometry. Subsequently, antimicrobial susceptibility testing was performed on 97 Nocardia clinical isolates against 13 antimicrobial agents. RESULTS: Species identification revealed Nocardia farcinica as the predominant species, accounting for 95.36% of all isolates. Morphological analysis following cultivation showed that Nocardia farcinica exhibited partial acid-fast staining characteristics, with a light blue background and faint red or pink filamentous bacilli displaying definitive branching structures. These features clearly distinguished it from the cord-like arrangements typically observed in mycobacteria. Antimicrobial susceptibility testing demonstrated that co-trimoxazole, amikacin, moxifloxacin, and linezolid were reliable therapeutic options. In contrast, the tested β-lactams, macrolides, and tetracyclines exhibited high resistance rates, limiting their clinical utility. CONCLUSION: This study elucidates the epidemiological characteristics and antimicrobial susceptibility profiles of Nocardia infections in Guangzhou, providing valuable insights for early diagnosis and targeted therapy. Morphological analysis serves as an effective tool for reducing the risk of misdiagnosing Nocardia as mycobacteria. Future efforts should focus on optimizing detection methods and conducting multicenter studies to better understand prevalence trends and resistance mechanisms, ultimately improving clinical management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。